View source for Template:Pharmacokinetics of long-acting injectable antipsychotics

{| class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="font-size:small; margin: 1em auto;"
|+ class="nowrap" | {{Navbar|Pharmacokinetics of long-acting injectable antipsychotics|mini=y}} {{Font|size=105%|<noinclude>[[Pharmacokinetics]]</noinclude><includeonly>Pharmacokinetics</includeonly> of <noinclude>[[depot effect|long-acting]]</noinclude><includeonly>long-acting</includeonly> <noinclude>[[intramuscular injection|injectable]]</noinclude><includeonly>injectable</includeonly> <noinclude>[[antipsychotic]]s</noinclude><includeonly>antipsychotics</includeonly>}}
|-
! Medication !! Brand name !! Class !! Vehicle !! Dosage !! T<sub>max</sub> !! t<sub>1/2</sub> single !! t<sub>1/2</sub> multiple !! logP<sup>c</sup> !! Ref
|-
| {{No selflink|Aripiprazole lauroxil}} || Aristada || {{No selflink|Atypical antipsychotic|Atypical}} || [[Water]]<sup>a</sup> || 441–1064&nbsp;mg/4–8&nbsp;weeks || 24–35&nbsp;days || ? || 54–57&nbsp;days || 7.9–10.0 || 
|-
| {{No selflink|Aripiprazole monohydrate}} || Abilify Maintena || {{No selflink|Atypical antipsychotic|Atypical}} || [[Water]]<sup>a</sup> || 300–400&nbsp;mg/4&nbsp;weeks || 7&nbsp;days || ? || 30–47&nbsp;days || 4.9–5.2 || 
|-
| {{No selflink|Bromperidol decanoate}} || Impromen Decanoas || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 40–300&nbsp;mg/4&nbsp;weeks || 3–9&nbsp;days || ? || 21–25&nbsp;days || 7.9 || <ref name="ParentToussaint1983">{{cite journal | vauthors = Parent M, Toussaint C, Gilson H | date = 1983 | title = Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation. | journal = Current Therapeutic Research | volume = 34 | issue = 1 | pages = 1–6 }}</ref>
|-
| {{No selflink|Clopentixol decanoate}} || Sordinol Depot || {{No selflink|Typical antipsychotic|Typical}} || [[Viscoleo]]<sup>b</sup> || 50–600&nbsp;mg/1–4&nbsp;weeks || 4–7&nbsp;days || ? || 19&nbsp;days || 9.0 || <ref name="pmid6931472">{{cite journal | vauthors = Jørgensen A, Overø KF | title = Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels | journal = Acta Psychiatrica Scandinavica. Supplementum | volume = 279 | pages = 41–54 | date = 1980 | pmid = 6931472 | doi = 10.1111/j.1600-0447.1980.tb07082.x }}</ref>
|-
| {{No selflink|Flupentixol decanoate}} || Depixol || {{No selflink|Typical antipsychotic|Typical}} || [[Viscoleo]]<sup>b</sup> || 10–200&nbsp;mg/2–4&nbsp;weeks || 4–10&nbsp;days || 8&nbsp;days || 17&nbsp;days || 7.2–9.2 || <ref name="pmid6931472" /><ref name="Reynolds1993">{{cite book | vauthors = Reynolds JE | date = 1993 | chapter = Anxiolytic sedatives, hypnotics and neuroleptics. | title = Martindale: The Extra Pharmacopoeia | edition = 30th | pages = 364–623 | publisher = Pharmaceutical Press | location = London }}</ref>
|-
| {{No selflink|Fluphenazine decanoate}} || Prolixin Decanoate || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 12.5–100&nbsp;mg/2–5&nbsp;weeks || 1–2&nbsp;days || 1–10&nbsp;days || 14–100&nbsp;days || 7.2–9.0 || <ref name="pmid6143748">{{cite journal | vauthors = Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR | title = Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches | journal = The Journal of Clinical Psychiatry | volume = 45 | issue = 5 Pt 2 | pages = 50–9 | date = May 1984 | pmid = 6143748 }}</ref><ref name="pmid444352">{{cite journal | vauthors = Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA | title = Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man | journal = British Journal of Clinical Pharmacology | volume = 7 | issue = 4 | pages = 325–31 | date = April 1979 | pmid = 444352 | pmc = 1429660 | doi = 10.1111/j.1365-2125.1979.tb00941.x }}</ref><ref name="YoungEreshefsky1984">{{cite conference | vauthors = Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N | title = Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.) | conference = 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. | location = Dallas, Texas | date = 1984 }}</ref>
|-
| {{No selflink|Fluphenazine enanthate}} || Prolixin Enanthate || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 12.5–100&nbsp;mg/1–4&nbsp;weeks || 2–3&nbsp;days || 4&nbsp;days || ? || 6.4–7.4 || <ref name="pmid444352" />
|-
| {{No selflink|Fluspirilene}} || Imap, Redeptin || {{No selflink|Typical antipsychotic|Typical}} || [[Water]]<sup>a</sup> || 2–12&nbsp;mg/1&nbsp;week || 1–8&nbsp;days || 7&nbsp;days || ? || 5.2–5.8 || <ref name="pmid4992598">{{cite journal | vauthors = Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK | title = The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug | journal = Arzneimittel-Forschung | volume = 20 | issue = 11 | pages = 1689–98 | date = November 1970 | pmid = 4992598 }}</ref>
|-
| {{No selflink|Haloperidol decanoate}} || Haldol Decanoate || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 20–400&nbsp;mg/2–4&nbsp;weeks || 3–9&nbsp;days || colspan="2" | 18–21&nbsp;days || 7.2–7.9 || <ref name="pmid3545764">{{cite journal | vauthors = Beresford R, Ward A | title = Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis | journal = Drugs | volume = 33 | issue = 1 | pages = 31–49 | date = January 1987 | pmid = 3545764 | doi = 10.2165/00003495-198733010-00002 }}</ref><ref name="pmid7185768">{{cite journal | vauthors = Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ | title = Pharmacokinetics of haloperidol decanoate. A 2-year follow-up | journal = International Pharmacopsychiatry | volume = 17 | issue = 4 | pages = 238–46 | date = 1982 | pmid = 7185768 | doi = 10.1159/000468580 }}</ref>
|-
| {{No selflink|Olanzapine pamoate}} || Zyprexa Relprevv || {{No selflink|Atypical antipsychotic|Atypical}} || [[Water]]<sup>a</sup> || 150–405&nbsp;mg/2–4&nbsp;weeks || 7&nbsp;days || ? || 30&nbsp;days || – || 
|-
| {{No selflink|Oxyprothepin decanoate}} || Meclopin || {{No selflink|Typical antipsychotic|Typical}} || ? || ? || ? || ? || ? || 8.5–8.7 || 
|-
| {{No selflink|Paliperidone palmitate}} || Invega Sustenna || {{No selflink|Atypical antipsychotic|Atypical}} || [[Water]]<sup>a</sup> || 39–819&nbsp;mg/4–12&nbsp;weeks || 13–33&nbsp;days || 25–139&nbsp;days || ? || 8.1–10.1 || 
|-
| {{No selflink|Perphenazine decanoate}} || Trilafon Dekanoat || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 50–200&nbsp;mg/2–4&nbsp;weeks || ? || ? || 27&nbsp;days || 8.9 || 
|-
| {{No selflink|Perphenazine enanthate}} || Trilafon Enanthate || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 25–200&nbsp;mg/2&nbsp;weeks || 2–3&nbsp;days || ? || 4–7&nbsp;days || 6.4–7.2 || <ref name="LarssonAxelsson1984">{{cite journal | vauthors = Larsson M, Axelsson R, Forsman A | title = On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. | journal = Current Therapeutic Research | date = 1984 | volume = 36 | issue = 6 | pages = 1071–88  }}</ref>
|-
| {{No selflink|Pipotiazine palmitate}} || Piportil Longum || {{No selflink|Typical antipsychotic|Typical}} || [[Viscoleo]]<sup>b</sup> || 25–400&nbsp;mg/4&nbsp;weeks || 9–10&nbsp;days || ? || 14–21&nbsp;days || 8.5–11.6 || <ref name="Reynolds1993" />
|-
| {{No selflink|Pipotiazine undecylenate}} || Piportil Medium || {{No selflink|Typical antipsychotic|Typical}} || [[Sesame oil]] || 100–200&nbsp;mg/2&nbsp;weeks || ? || ? || ? || 8.4 || 
|-
| {{No selflink|Risperidone}} || Risperdal Consta || {{No selflink|Atypical antipsychotic|Atypical}} || [[Microsphere]]s || 12.5–75&nbsp;mg/2&nbsp;weeks || 21&nbsp;days || ? || 3–6&nbsp;days || – || 
|-
| {{No selflink|Zuclopentixol acetate}} || Clopixol Acuphase || {{No selflink|Typical antipsychotic|Typical}} || [[Viscoleo]]<sup>b</sup> || 50–200&nbsp;mg/1–3&nbsp;days || 1–2&nbsp;days || colspan="2" | 1–2 days<!--32–36 hours--> || 4.7–4.9 || 
|-
| {{No selflink|Zuclopentixol decanoate}} || Clopixol Depot || {{No selflink|Typical antipsychotic|Typical}} || [[Viscoleo]]<sup>b</sup> || 50–800&nbsp;mg/2–4&nbsp;weeks || 4–9&nbsp;days || ? || 11–21&nbsp;days || 7.5–9.0 || 
|- class="sortbottom"
| colspan="10" style="width: 1px; background-color:#eaecf0; background-color:#eaecf0; text-align: center;" | '''Note:''' All by [[intramuscular injection]]. '''Footnotes:''' <sup>a</sup> = [[Microcrystalline]] or [[nanocrystalline]] [[aqueous suspension]]. <sup>b</sup> = Low-[[viscosity]] [[vegetable oil]] (specifically [[fractionated coconut oil]] with [[medium-chain triglyceride]]s). <sup>c</sup> = Predicted, from [[PubChem]] and [[DrugBank]]. '''Sources:''' ''Main:'' <noinclude><ref name="pmid7520856">{{cite journal | vauthors = Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L | title = Depot antipsychotic drugs. Place in therapy | journal = Drugs | volume = 47 | issue = 5 | pages = 741–73 | date = May 1994 | pmid = 7520856 | doi = 10.2165/00003495-199447050-00004 }}</ref><ref name="pmid2864156">{{cite journal | vauthors = Jann MW, Ereshefsky L, Saklad SR | title = Clinical pharmacokinetics of the depot antipsychotics | journal = Clinical Pharmacokinetics | volume = 10 | issue = 4 | pages = 315–33 | date = 1985 | pmid = 2864156 | doi = 10.2165/00003088-198510040-00003 }}</ref><ref name="DenckerAxelsson1996">{{cite journal| vauthors = Dencker SJ, Axelsson R |title=Optimising the Use of Depot Antipsychotics|journal=CNS Drugs|volume=6|issue=5|year=1996|pages=367–381 |doi=10.2165/00023210-199606050-00004}}</ref><ref name="pmid26585875">{{cite journal | vauthors = Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM | title = The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values | journal = CNS Drugs | volume = 29 | issue = 12 | pages = 975–83 | date = December 2015 | pmid = 26585875 | doi = 10.1007/s40263-015-0295-2 }}</ref><ref name="pmid23343447">{{cite journal | vauthors = Spanarello S, La Ferla T | title = The pharmacokinetics of long-acting antipsychotic medications | journal = Current Clinical Pharmacology | volume = 9 | issue = 3 | pages = 310–7 | date = 2014 | pmid = 23343447 | doi = 10.2174/15748847113089990051 }}</ref><ref name="pmid29350127">{{cite journal | vauthors = Meyer JM | title = Converting oral to long-acting injectable antipsychotics: a guide for the perplexed | journal = CNS Spectrums | volume = 22 | issue = S1 | pages = 14–28 | date = December 2017 | pmid = 29350127 | doi = 10.1017/S1092852917000840 }}</ref><ref name="Taylor2018">{{cite journal| vauthors = Taylor D |title=Depot antipsychotics revisited|journal=Psychiatric Bulletin|volume=23|issue=9|year=2018|pages=551–553|issn=0955-6036 |doi=10.1192/pb.23.9.551 }}</ref><ref name="SteinWilkinson2007">{{cite book| vauthors = Stein G, Wilkinson G |title=Seminars in General Adult Psychiatry|url=https://books.google.com/books?id=6PGzHFuS1xkC&pg=PA254|date=April 2007|publisher=RCPsych Publications|isbn=978-1-904671-44-2|pages=254–}}</ref><ref name="GardnerMurphy2014">{{cite journal| vauthors = Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ |title=International Consensus Study of Antipsychotic Dosing|journal=FOCUS|volume=12|issue=2|year=2014|pages=235–243|issn=1541-4094|doi=10.1176/appi.focus.12.2.235}}</ref><ref name="M.Z.2019">{{cite book| vauthors = Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ |title=Clinical Handbook of Psychotropic Drugs|url=https://books.google.com/books?id=EzaaDwAAQBAJ&pg=PA137|date=15 May 2019|publisher=Hogrefe Verlag|isbn=978-1-61676-561-3|pages=137–}}</ref><ref name="Kapfhammer1990">{{cite book| vauthors = Kapfhammer HP |chapter=Umstellungsregime von Kurzzeit- auf Depotneuroleptika|trans-chapter=Changeover regime from short-term to depot neuroleptics|year=1990|pages=173–198|doi=10.1007/978-3-642-75194-3_18|title=Thioxanthene in der Neuroleptischen Behandlung|trans-title=Thioxanthenes in Neuroleptic Treatment}}</ref><ref name="WrightBurgess2012">{{cite book| vauthors = Wright JC, Burgess DJ |title=Long Acting Injections and Implants|url=https://books.google.com/books?id=36nkGjEGEToC&pg=PA114|date=29 January 2012|publisher=Springer Science & Business Media|isbn=978-1-4614-0554-2|pages=114–117}}</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
== References ==
{{Reflist}}
}}
[[Category:Antipsychotics]]
[[Category:Antipsychotic esters]]
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>